Spain HIV Therapeutics Market Report 2022 to 2030

Spain HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Spain HIV therapeutics market will reach a value of $304 Mn from $266 Mn in 2022, growing at a CAGR of 1.7% during 2022-2030. The market is primarily dominated by local players such as Cinfa, Almirall, and Gilead sciences. The market is driven by various financial initiatives, increasing awareness campaigns, and stringent regulatory laws. The HIV therapeutics market in Spain is segmented by type, product, and geography, end user, and distribution channel.

ID: IN10ESPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Spain AUTHOR: Dr. Vishwa Modhia

Buy Now

Spain HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Spain HIV therapeutics market will reach a value of $304 Mn from $266 Mn in 2022, growing at a CAGR of 1.7% during 2022-2030.

Spain's adult HIV/AIDS prevalence rate is expected to be 0.3% by the year 2021. Compared to other countries, Spain is ranked 86th in its HIV prevalence. In 2019, the Spanish government's healthcare expenditures accounted for 9.1% of its GDP. With an estimated total of 150,000 people living with HIV/AIDS as of 2021, Spain has one of the lowest rates of HIV/AIDS in all of Europe. Coordination of the country's HIV/AIDS policy as well as funding for programs and studies pertaining to the disease falls under the purview of the Spanish Ministry of Health, Social Services, and Equality.

The Spanish AIDS Foundation (Fundación Española del SIDA), which supports and advocates for those living with HIV/AIDS and works to spread awareness of the disease, is one of a number of HIV/AIDS organizations that are well-established in Spain. Spain also intends to make investments to encourage sustainability and rationalize the use of pharmaceutical products.

spain HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers Analysis

Around 6% of clinical trials in Spain in 2020 were based on the immunology therapeutic field, which could be a major driver of the country's HIV therapeutics market. Spain has increased its funding for initiatives to enhance health promotion and prevention of conditions like HIV infection. In order to stop the spread of HIV among drug injectors, Spain has been at the forefront of harm reduction strategies, offering opioid substitution therapy (OST) and needle exchange programs.

Market Restraints

Spain suffers from a medical workforce shortage, especially in rural areas, which can make it challenging to provide the necessary care and treatment for communicable diseases like HIV AIDS. Spain has a universal healthcare system, but in some rural and remote areas, access to care may be restricted. For those living in these areas, getting access to medical care and treatment may be challenging.

Competitive Landscape

Key Players

Cinfa (ESP)
Almirall (ESP)
Grifols (ESP)
Rovi (ESP)
Gilead sciences (ESP)
Boehringer Ingelheim (ESP)
Novartis
Sanofi
Normon
Moderna
GlaxoSmithKline

Healthcare Policies

The Spanish Ministry of Health, a branch of the central government of Spain, is in charge of, among other things, developing and enforcing regulations regarding the cost and reimbursement of pharmaceuticals purchased with public funds in Spain.

The Spanish Medicines Agency for Medicinal Products and Medical Devices (i.e., Agencia Española de Medicamentos y Productos Sanitarios, or "AEMPS"), which is also part of the central Spanish government, is responsible, among others, for granting marketing authorizations for medicinal products in Spain through national, mutual-recognition, or decentralized procedures.

Reimbursement Scenarios

Since they need prior approval from the Ministry of Health/CIPM, the prices of medicines that are reimbursed cannot be freely set by the marketer. Additionally, the Ministry of Health/CIPM may regulate the cost of pharmaceuticals that are not eligible for reimbursement if there are valid public reasons. All medical supplies and equipment that are given out in hospitals are paid for by the NHS. On the other hand, copayment policies that require the patient to pay a portion of the product's cost to apply to medications that patients purchase from retail pharmacies.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.